What is HC Wainwright’s Forecast for Vericel Q3 Earnings?

Vericel Co. (NASDAQ:VCEL) – Research analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of Vericel in a report issued on Wednesday, January 15th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.05 per share for the quarter, down from their previous estimate of $0.09. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Vericel’s Q4 2025 earnings at $0.26 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.86 EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $2.02 EPS.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million.

VCEL has been the subject of several other reports. BTIG Research lifted their price objective on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Tuesday, November 19th. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. Stephens reaffirmed an “overweight” rating and set a $65.00 target price on shares of Vericel in a report on Wednesday. Finally, Truist Financial increased their price target on shares of Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Vericel presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.14.

Vericel Stock Up 4.8 %

Shares of Vericel stock opened at $59.07 on Friday. The firm has a market capitalization of $2.92 billion, a P/E ratio of 984.66 and a beta of 1.72. Vericel has a 52 week low of $37.36 and a 52 week high of $61.49. The company has a 50 day moving average price of $57.03 and a 200 day moving average price of $50.03.

Institutional Trading of Vericel

Several institutional investors have recently bought and sold shares of VCEL. International Assets Investment Management LLC raised its stake in shares of Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the period. Farther Finance Advisors LLC increased its holdings in Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 322 shares during the period. Meeder Asset Management Inc. purchased a new position in Vericel during the third quarter valued at $92,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Vericel in the third quarter valued at about $146,000.

Insider Activity

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the sale, the director now owns 26,595 shares in the company, valued at approximately $1,595,700. This trade represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul K. Wotton sold 2,600 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $58.72, for a total transaction of $152,672.00. Following the completion of the transaction, the director now owns 27,402 shares of the company’s stock, valued at approximately $1,609,045.44. This trade represents a 8.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,100 shares of company stock valued at $889,872 in the last three months. 7.20% of the stock is currently owned by corporate insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.